Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abciximab in Wake-Up Stroke
NCT00167765Phase 3Terminated
- Sponsor
- University of Zurich
- Start
- Mar 2005
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of abciximab in ischemic stroke, sponsored by University of Zurich. Started Mar 2005; status: terminated.
02
Drugs
abciximab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00167765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00167765.